Sort
15,273 grants matching “antimicrobial resistance”
Biology of Infectious Diseases Training Program
$230,466Henry F Chambers · University Of California, San Francisco · T32 · FY2013 · AI
Antimicrobial peptide mimetic activity against Candida auris
$230,417Gill Diamond · University Of Louisville · R21 · FY2022 · AI
Structure, Function and Inhibition of Beta-lactamases
$230,397University Of California San Francisco · R01 · FY2005 · GM
Stenotrophomonas maltophilia TfcA and TfcB: Antibacterial T4SS effectors from an emerging human pathogen
$230,295Nicholas Philip Cianciotto · Northwestern University At Chicago · R21 · FY2023 · AI
Molecular Detection of Invasive Fungal Infections by Reverse Line Blot Assay
$230,256Andrew E. Levin · Immunetics, Inc. · R21 · FY2010 · AI
Development of a prototype Klebsiella O polysaccharide conjugate vaccine
$230,250Alan S Cross · University Of Maryland Baltimore · R21 · FY2015 · AI
Targeting polymicrobial infections of diabetic foot ulcers with a novel antimicrobial peptide therapy
$230,250Dragana Ajdic · University Of Miami School Of Medicine · R21 · FY2022 · AI
Novel Metallo-beta-lactamase Inhibitors
$230,250Yongcheng Song · Baylor College Of Medicine · R21 · FY2010 · AI
Molecular Basis of Human Defensins as Novel Lipid II Binding Peptide Antibiotics
$230,250Erik De Leeuw · University Of Maryland Baltimore · R21 · FY2011 · AI
Probing the role of sensory cues in the regulation of bacterial biofilm development
$230,247Sampriti Mukherjee · University Of Chicago · R35 · FY2024 · GM
Allosteric Modulation of the Multidrug Transporter MDR1
$230,237Saibal Dey · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2008 · GM
The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis
$230,199Samuel M Behar · Brigham And Women'S Hospital · R21 · FY2012 · AI
Role of IFNs and IFNGR in susceptibility to bacteria in Down syndrome
$230,121Laurel L Lenz · University Of Colorado Denver · R21 · FY2021 · AI
Evaluation of Novel Antimicrobial Agents and a Novel Shuttle Vector
$230,058Mark R Liles · Auburn University At Auburn · R21 · FY2009 · AI
Targeted Antimicrobial Treatment of Acne Vulgaris with a novel class of Enzybiotics from Mycobacteriophage lysterases
$229,997James K. Wang · Dermalytica, Inc. · R43 · FY2016 · AR
Inhibition of prokaryote-specific saccharide biosynthesis in microbial pathogens
$229,962Barbara Imperiali · Massachusetts Institute Of Technology · R01 · FY2012 · GM
Stimuli-Responsive Polymer-Drug Conjugates: A New Strategy to Fight Antimicrobial Resistance
$229,920Shaoqin - Gong · University Of Wisconsin-Madison · R21 · FY2022 · AI
Biology of Infectious Diseases Training Program
$229,911Henry F Chambers · University Of California, San Francisco · T32 · FY2012 · AI
A "radical" approach to tuberculosis infection
$229,839Deborah T Hung · Broad Institute, Inc. · R21 · FY2014 · AI
Pseudomonas Genomic Signatures Associated With Persistence in Cystic Fibrosis
$229,642Alan R Hauser · Northwestern University At Chicago · R21 · FY2016 · HL
Overcoming Pyrazinamide Resistance with Pyrazinoate-Cephalosporin Conjugates
$229,632Courtney C Aldrich · University Of Minnesota · R21 · FY2020 · AI
The in vivo effect of vitamin D on Mycobacterium tuberculosis infection
$229,628Padmini Salgame · Rbhs-New Jersey Medical School · R21 · FY2016 · AI
The role of PMNs and CD73 in host-resistance against S. pneumoniae / influenza A virus co-infection
$229,575Elsa Bou Ghanem · State University Of New York At Buffalo · R21 · FY2023 · AI
Type II-NDHs in M. tuberculosis respiration and persistence
$229,500Thomas C. Zahrt · Medical College Of Wisconsin · R21 · FY2016 · AI
Metal withholding responses in the gut mucosa
$229,500Manuela Raffatellu · University Of California-Irvine · R21 · FY2009 · AI